Apixaban Dosing and Efficacy in Atrial Fibrillation

Introduction to Apixaban Therapy

The American Heart Association recommends apixaban at a dose of 5 mg taken orally twice daily for stroke prevention in nonvalvular atrial fibrillation, which has been shown to be superior to warfarin in preventing stroke and systemic embolism in patients with nonvalvular atrial fibrillation (1.27% vs 1.60% per year; HR 0.79) 1, 2
Apixaban also demonstrated lower rates of major bleeding compared to warfarin (2.13% vs 3.09% per year; HR 0.69) and reduced all-cause mortality (3.52% vs 3.94%; p=0.047) 1, 2

Atrial dilation increases thromboembolic risk, making proper anticoagulation particularly important in these patients 3
Left atrial dilation is associated with an increased risk of thrombus formation, even in patients on adequate anticoagulation 4
In patients with atrial dilation, proper anticoagulation is critical as they may be at higher risk for thromboembolic events 3, 4

While routine coagulation monitoring is not required for apixaban, patients should be monitored for signs of bleeding or thrombosis 4
If procedures are needed, apixaban should be discontinued 24-48 hours prior depending on bleeding risk, not abruptly stopped without a plan 3, 5

For patients requiring cardioversion, apixaban can be continued without interruption, with the dose taken 4 hours before the procedure 4, 6, 7
In patients with left atrial thrombus, apixaban has shown efficacy in thrombus resolution (52% resolution rate) 7